{
    "clinical_study": {
        "@rank": "102627", 
        "acronym": "RESGEX", 
        "arm_group": [
            {
                "arm_group_label": "CetuGEX\u2122 plus chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "60 mg/day 0, 930 mg/day 1, followed by 720 mg weekly administration"
            }, 
            {
                "arm_group_label": "Cetuximab plus chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "400 mg/m2 on day 1, followed by 250 mg/m2 weekly administration"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the efficacy of CetuGEX\u2122 for the treatment of patients\n      with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in\n      combination with platinum-based chemotherapy) in terms of progression-free survival (PFS)."
        }, 
        "brief_title": "CetuGEX\u2122 in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer", 
        "condition": "Carcinoma, Squamous Cell of Head and Neck", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with histologically confirmed recurrent and/or metastatic EGFR-positive\n             SCCHN not eligible for local treatment.\n\n          2. Patients with measurable disease according to Response Evaluation Criteria in Solid\n             Tumors (RECIST) 1.1.\n\n          3. Patients aged at least 18 years at screening.\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          5. Minimum life expectancy of 3 months.\n\n          6. Tissue samples available for specific disease and therapy related biological\n             assessments.\n\n          7. If female and of childbearing potential, is non-lactating and has negative pregnancy\n             test results at screening and prior to randomization.\n\n          8. If female, is either not of childbearing potential or using highly effective\n             contraceptives.\n\n          9. Willing and able to comply with the protocol.\n\n         10. Willing and able to provide written informed consent.\n\n        Exclusion Criteria:\n\n          1. Prior systemic chemotherapy (except if given as part of a multimodal treatment for\n             locally advanced disease which was completed more than 6 months prior to screening).\n\n          2. Cetuximab or other EGFR targeting agent treatment (except if given as part of a\n             multimodal treatment for locally advanced disease which was completed more than 6\n             months prior to screening).\n\n          3. Surgery (other than minor interventions like diagnostic biopsy or intravenous port\n             implantation) or irradiation within 30 days before randomization.\n\n          4. Concomitant anti-tumor therapy or concomitant immunotherapy.\n\n          5. Concomitant corticosteroid treatment unless specified within the protocol.\n\n          6. Clinical evidence of brain metastasis or leptomeningeal involvement.\n\n          7. Patients with nasopharyngeal tumors.\n\n          8. Concomitant malignant disease, except for adequately treated tumors with high\n             likelihood of being cured (e.g., basal cell cancer of the skin, cervical cancer or\n             breast cancer in situ). Patients with other previous malignancies but without\n             evidence of disease for at least 5 years will be allowed to enter the study.\n\n          9. Patients with renal or hepatic impairment.\n\n         10. Clinically active infections \u2265 Grade 2 using National Cancer Institute (NCI) Common\n             Terminology Criteria for Adverse Events (CTCAE) version 4 and/or requiring\n             intravenous antibiotics.\n\n         11. Known active hepatitis B or C.\n\n         12. Known human immunodeficiency virus (HIV) infection.\n\n         13. Myocardial infarction within 6 months prior to screening.\n\n         14. Symptomatic congestive heart failure (New York Heart Association [NYHA] Grade 3 or\n             4), unstable angina pectoris within 6 months prior to screening, significant cardiac\n             arrhythmia, history of stroke or transient ischemic attack within 1 year prior to\n             screening.\n\n         15. History of keratitis requiring medical interventions within the last 5 years.\n\n         16. Patients with any other disorder that, in the opinion of the investigator, might\n             interfere with the conduct of the study.\n\n         17. Patients with an unstable condition (e.g., psychiatric disorder, a recent history of\n             drug or alcohol abuse, interfering with study compliance, within 6 months prior to\n             screening) or otherwise thought to be unreliable or incapable of complying with the\n             requirements of the protocol.\n\n         18. Patients institutionalized by official means or court order.\n\n         19. Receipt of any other investigational medicinal product within the last 30 days before\n             randomization or any previous CetuGEX\u2122 administration.\n\n         20. Prior allergic reaction to a monoclonal antibody, grade 3 infusion related reaction\n             (IRR) or any grade 4 reaction to a monoclonal antibody.\n\n         21. Known sensitivity to any component of the investigational medicinal product (IMP) and\n             medication used in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052960", 
            "org_study_id": "GEXMab52201"
        }, 
        "intervention": [
            {
                "arm_group_label": "CetuGEX\u2122 plus chemotherapy", 
                "intervention_name": "CetuGEX\u2122", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cetuximab plus chemotherapy", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "CetuGEX\u2122 plus chemotherapy", 
                    "Cetuximab plus chemotherapy"
                ], 
                "description": "Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)", 
                "intervention_name": "Combination of Cisplatin and 5-Fluorouracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cetuximab", 
                "Cisplatin", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Avignon", 
                        "country": "France", 
                        "zip": "84918"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69008"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34298"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06189"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12203"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "zip": "25123"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "zip": "27100"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brasov", 
                        "country": "Romania", 
                        "zip": "500091"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clui-Napoca", 
                        "country": "Romania", 
                        "zip": "400015"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Craiova", 
                        "country": "Romania", 
                        "zip": "200385"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oradea", 
                        "country": "Romania", 
                        "zip": "410469"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ploiesti", 
                        "country": "Romania", 
                        "zip": "100011"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Timisoara", 
                        "country": "Romania", 
                        "zip": "300239"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Timisoara", 
                        "country": "Romania", 
                        "zip": "300167"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28911"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28223"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46009"
                    }, 
                    "name": "Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Italy", 
                "Romania", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX\u2122 Plus Chemotherapy in Comparison to Cetuximab Plus Chemotherapy for the Treatment of Patients With Stage III/IV Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck", 
        "overall_contact": {
            "last_name": "Glycotope GmbH", 
            "phone": "0049-30-9489-2600"
        }, 
        "overall_official": {
            "affiliation": "Charit\u00e9 Berlin", 
            "last_name": "Ulrich Keilholz, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Paul-Ehrlich-Institut", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Italy: The Italian Medicines Agency", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the efficacy of CetuGEX\u2122 in terms of progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Glycotope GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glycotope GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}